Last reviewed · How we verify
NCT06826313
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
Phase 1 trial testing VRT106 in Solid Tumors in 12 participants. Currently enrolling.
30 December 2025
Quick facts
| Lead sponsor | Guangzhou Virotech Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 19 March 2025 |
| Primary completion | 30 December 2025 |
| Estimated completion | 1 March 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- VRT106 — full drug profile →
Conditions studied
- Solid Tumors — all drugs for Solid Tumors →
Sponsor
Guangzhou Virotech Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer.
Jin S, Zhang Y, Zhou Z, Zhang Y, et al · · 2026 · PMID 41970230 · DOI 10.1002/mco2.70725
Verify or expand the search:
- PubMed search for NCT06826313
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VRT106
Trials testing the same drug.
- NCT07486310 — Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastri · Phase 2 · not yet recruiting
- NCT07093814 — A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma · Phase 1, PHASE2 · recruiting
Other recruiting trials for Solid Tumors
Currently open trials in the same condition.
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
- NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
- NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
- NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting
Other Guangzhou Virotech Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07093814 — A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma · Phase 1, PHASE2 · recruiting
- NCT06046742 — A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06826313 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Virotech Pharmaceutical Co., Ltd.
- Last refreshed: 18 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06826313.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing